Andere Sprachen Voyager Therapeutics, Inc.

Aktien

A143XJ

US92915B1061

VYGR

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:28:44 28.06.2024			% 5 Tage	% 1. Jan.
7,875 ^USD	+0,19 %		-3,09 %	-7,11 %

13.06.	Voyager Therapeutics, Inc. ernennt Nathan Jorgensen zum Principal Financial Officer und Principal Accounting Officer, mit Wirkung bis spätestens 8. Juli 2024	CI
16.05.	Voyager Therapeutics, Inc. gibt die Verabreichung der ersten Teilnehmer in der Studie mit VY-TAU01 zur Behandlung der Alzheimer-Krankheit in aufsteigender Einzeldosis bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences	13.06.
Voyager Therapeutics Names Nathan Jorgensen as Finance Chief	13.06.
Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Principal Financial Officer, and Principal Accounting Officer, Effective No Later Than July 8, 2024	13.06.
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer	13.06.
Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024	13.06.
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease	16.05.
Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer?s Disease	16.05.
Voyager Therapeutics: Q1 Earnings Snapshot	13.05.
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results	13.05.
Voyager Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Voyager Therapeutics Presents Data for Second-Generation, TRACER-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	09.05.
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	08.05.
Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER??-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting	08.05.
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast	06.05.
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	22.04.
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS	16.04.
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	16.04.
Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer	02.04.
Voyager Therapeutics, Inc. Announces CFO Changes	02.04.
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	27.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Voyager Therapeutics, Inc.

Aktien

A143XJ

US92915B1061

VYGR

Andere Sprachen

Filter